The Patent Finder

Institut Gustave Roussy

25 patents currently held · Updated Nov 16, 2026
21 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

2
Ending by 2030
Aug 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 7, 2027
    The maintenance fee for Novel Derivatives of Oxazaphosphorines That Are Pre-Activated, Use and Method of Preparation (US 9,073,957) comes due Jan 7, 2027. Unpaid by Jul 7, 2027, it lapses early.
  • 2 fees due Feb 22, 2027
  • 1 fee due Aug 11, 2027
    The maintenance fee for Diagnostic of chronic myelomonocytic leukemia (CMML) by flow cytometry (US 10,557,849) comes due Aug 11, 2027. Unpaid by Feb 11, 2028, it lapses early.
  • 1 fee due Oct 16, 2027
    The maintenance fee for Means for transporting persons with reduced mobility comprising a device with for connecting to aserum holder, associated connecting assembly (US 11,957,868) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,980,280Recombinant Feline Leukemia Virus Vaccine Containing Optimized Feline Leukemia Virus Envelope Gene
In force
 · Low confidence
In forceLow confidence
US 11,203,788TET2 as a Diagnostic and Pronostic Marker in Hematopoietic Neoplasms
In force
 · High confidence
In forceHigh confidence
US 9,073,957Novel Derivatives of Oxazaphosphorines That Are Pre-Activated, Use and Method of Preparation
In force
 · High confidence
In forceHigh confidence
US 9,428,530Novel Derivatives of Oxazaphosphorines That Are Pre-Activated, Use and Method of Preparation
In force
 · Medium confidence
In forceMedium confidence
US 8,895,027Recombinant Feline Leukemia Virus Vaccine Containing Optimized Feline Leukemia Virus Envelope Gene
In force
 · High confidence
In forceHigh confidence
US 11,344,586Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatment
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,098,901Novel Derivatives of Oxazaphosphorines and Therapeutic Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,899,838Antibody Which Is Directed Against GALECTIN-9 and Is an Inhibitor of the Suppressor Activity of Regulatory T Lymphocytes
In force
 · High confidence
In forceHigh confidence
US 12,516,125Antibody which is Directed Against Galectin-9 and is an Inhibitor of the Suppressor Activity of Regulatory T Lymphocytes
In force
 · Medium confidence
In forceMedium confidence
US 10,765,710Combination of oncolytic virus with immune checkpoint modulators
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 25 patents shown.
Pro members see all 25.
Pro members: see all 25 patents
Also on record, not counted in the 25: 21 patents in force now held by others · 37 lapsed for an unpaid fee · 29 ended at full term · 1 past the fee grace period. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

15 pending · 25 abandoned · 23 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited